Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | MARS1 | P56192 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676477 | 0.93 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL1676534 | 0.90 | SUV39H2 (0.41) | NPC1RAB9ASMN1; SMN2POLBKDM4E | |
| SCHEMBL1676521 | 0.90 | KDM4E (0.43) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676531 | 0.89 | PTGES (0.45) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676161 | 0.89 | MARS1 (0.45) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676702 | 0.88 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676001 | 0.88 | KDM4E (0.41) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676770 | 0.87 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2POLBCNR1 | |
| SCHEMBL1676974 | 0.87 | PTGES (0.43) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP | |
| SCHEMBL1676222 | 0.86 | BCL2L1 (0.42) | NPC1RAB9ASMN1; SMN2KDM4ECRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | NPC1 3228/4885RAB9A 3396/4885SMN1; SMN2 4417/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NPC1 3228/4885RAB9A 3396/4885SMN1; SMN2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.